REGN Stock Price, Chart, Stats & News
Regeneron Pharmaceuticals, Inc. (REGN) is a dividend-paying stock with a current dividend yield of 0.55% as of Jul 15, 2026. It pays $3.64 per share over the trailing twelve months and distributes quarterly.
Dividend safety
Dividend coverage looks healthy — REGN pays out about 8% of earnings.
REGN chart
Fundamentals
Gross margin | 85.35% |
Operating margin | 24.95% |
Pretax margin | 36.47% |
Net margin | 31.41% |
Effective tax rate | 13.88% |
ROA | 11.11% |
ROE | 14.83% |
D/E | 0.09x |
Interest coverage ratio | 81.69x |
REGN valuation
P/E | 14.56x |
P/S | 5.34x |
P/B | 2.43x |
P/CF | 15.25x |
P/FCF | 18.78x |
P/OCF | 15.25x |
PEG | -22.87x |
EV multiple | 13.25x |
About
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients.
Related lists
Similar securities
Based on sector and market capitalization
